



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov

## \*BIBDATASHEET\*

Bib Data Sheet

CONFIRMATION NO. 2403

SERIAL NUMBER 10/076,575	FILING DATE 02/08/2002 RULE	CLASS 514	GROUP ART UNIT 1624	ATTORNEY DOCKET NO. 5698.220-US
-----------------------------	-----------------------------------	--------------	------------------------	------------------------------------

## APPLICANTS

Lone Jeppesen, Virum, DENMARK;

Paul Stanley Bury, Kobenhavn, DENMARK;  
Per Sauerberg, Farum, DENMARK;

## \*\* CONTINUING DATA \*\*\*\*\*

This application is a DIV of 09/419,761 10/19/1999 PAT 6,468,996  
and claims benefit of 60/105,912 10/28/1998

## \*\* FOREIGN APPLICATIONS \*\*\*\*\*

DENMARK PA 1998 01352 10/21/1998

## IF REQUIRED, FOREIGN FILING LICENSE GRANTED

\*\* 03/07/2002

Foreign Priority claimed 35 USC 119 (a-d) conditions met	<input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance	STATE OR COUNTRY DENMARK	SHEETS DRAWING 0	TOTAL CLAIMS 10	INDEPENDENT CLAIMS 1
Verified and Acknowledged Examiner's Signature	<i>Brenda Coleman BC</i> Initials				

## ADDRESS

Reza Green, Esq.  
 Novo Nordisk of North America, Inc.  
 100 College Rd. W.  
 Princeton, NJ  
 08540-6604

## TITLE

Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators

FILING FEE	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit
RECEIVED 740		